Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 for COVID-19 in Cancer Patients
NCT04419623Phase 1Completed
- Sponsor
- Telios Pharma
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TL-895 in coronavirus disease 2019 (COVID-19), sponsored by Telios Pharma. Primary endpoint: Recommended dose of TL-895 at Day 14. Started Jul 2020; status: completed.
02
Drugs
TL-895
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04419623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419623.